Back to results
US 6,638,943 B2Granted
Yohimbine dimers exhibiting binding selectivities for α2 adrenergic receptors
AssigneeUniversity of Tennessee Research Foundation
InventorsDuane D. Miller, Weiping Zheng, Bob M. Moore, II, Suni Mustafa
Life of this patent
Estimating the term…
Abstract
The present invention relates to yohimbine dimer compounds, pharmaceutical compositions containing such dimer compounds, methods of making such dimer compounds, and uses thereof. The yohimbine dimer compounds include compounds of formula (I): where R is any linker molecule which affords a yohimbine dimer that has activity as an α2-AR antagonist and has selectivity for an α2-AR subtype over another α2-AR subtype.
Claims26
A compound according to formula (I)
- wherein R is a linker molecule having a length of about 2.5 Å to about 45 Å.
A compound according to formula (I)
- wherein R is a straight or branched chain alkyl, alkenyl, alkynyl comprising at least 2 carbon atoms in a main chain thereof;
- or
- wherein R is a straight or branched chain alkyl, alkenyl, alkynyl comprising at least 2 carbon atoms in a main chain thereof and an X group within the main chain and/or a Y group as a substituent linked to a carbon atom in the main chain,
- with X being —O—, carbonyl, —NR1— with R1 being H or an alkyl, —C(O)NHR1— with R1 being an alkyl, —S—, sulfoxide, sulfonyl, or a cyclic or multicyclic ring with or without hetero atoms as ring members and including, optionally, one or more substitutions on the ring structure, and
- with Y being —OH, —NO2, —CN, —C(O)H, —SH, a primary, secondary, or tertiary amine, a carboxylic acid, an ester, a keto group, —SO2NH2, or —SO2NHR2 with R2 being an alkyl;
- or
- wherein R is a cyclic or multicyclic ring with or without hetero atoms as ring members and including, optionally, one or more substitutions on the ring structure(s).
4 more elements
Dependencies are inferred from the claim text.